Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(Astellas) 7465-CL-0301An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)Hotte, Dr SebastienOpen to recruitmentNCT03474107
(AstraZeneca) D419JC00001 / POTOMACA Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG-Naïve Non-Muscle-Invasive Bladder Cancer Patients (POTOMAC)Hotte, Dr SebastienOpen to recruitmentNCT03528694
(AstraZeneca) D933SC00001 / NILEA Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial CancerHotte, Dr SebastienOpen to recruitmentNCT03682068
(BMS) CA018005 / FRACTION-RCCA Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in
Participants with Advanced Renal Cell Carcinoma
Hotte, Dr SebastienOpen to recruitmentNCT02996110
(BMS) CA2099KD / CheckMate 9KDA Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or
Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer (CheckMate 9KD:
CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9KD)
Hotte, Dr SebastienOpen to recruitmentNCT03338790
(CCTG) IND.234 / PC-BETS - Master ProtocolProstate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening ProtocolMukherjee, Dr SomOpen to recruitmentNCT03385655 (Master)
(CCTG) IND.234 / PC-BETS - Sub-Study IND.223A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients With Metastatic Castration-Resistant Prostate CancerMukherjee, Dr SomOpen to recruitmentNCT02905318
(CCTG) IND.234B/PC-BETS Sub-Study BA Phase II Study of Savolitinib, A CMET Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234Mukherjee, Dr SomOpen to recruitmentNCT03385655(B)
(CCTG) IND.234C/PC-BETS Sub-Study CA Phase II Study of Darolutamide (ODM-201) in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate or Enzalutamide - A Sub-Study of IND.234Mukherjee, Dr SomOpen to recruitmentNCT03385655(C)
(Clovis) CO-338-052 / TRITON2A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination DeficiencyHotte, Dr SebastienOpen to recruitmentNCT02952534
(JCC) Prostate HBINon-Targeted Low Dose Radiotherapy For Recurrent Prostate CancerDayes, Dr IanOpen to recruitmentNCT03196778
(JGH) PCS IX / PCS 9The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer With Oligometastases: An Adaptive Phase II/III Randomized Trial.Tsakiridis, Dr TheosOpen to recruitmentNCT02685397
(Merck) MK-3475-564 / KEYNOTE 564A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)Lalani, Dr Aly-KhanOpen to recruitmentNCT03142334
(Merck) MK-3475-641 / KEYNOTE 641A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)Lalani, Dr Aly-KhanOpen to recruitmentNCT03834493
(Merck) MK-3475-921 / KEYNOTE 921A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA)Lalani, Dr Aly-KhanOpen to recruitmentNCT03834506
(Merck) MK-7339-010 / KEYLYNK-010Phase 3, Randomized, Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and ChemotherapyLalani, Dr Aly-KhanOpen to recruitmentNCT03834519
(Bayer) BAY 1163877 / 17403 / FORT-1A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of
rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive
locally advanced or metastatic urothelial carcinoma who have received prior platinum containing
Hotte, Dr SebastienSuspended/On holdNCT03410693
(CCTG) IND.234A/PC-BETS Sub-Study AA Phase II Study of AZD1775, A WEE1 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234Mukherjee, Dr SomSuspended/On holdNCT03385655 (A)
(JCC) The PBS StudyA randomized phase II trial investigating Stereotactic Body RadioTherapy (SBRT) for prostate boost irradiation in the treatment of high risk Prostate Cancer (PrCa)Tsakiridis, Dr TheosSuspended/On holdNCT03380806
OCOG-2013-PETMUSEImpact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder StagingMukherjee, Dr SomSuspended/On holdNCT02462239
Download PDF